Immuneering Corp. Class A IMRX
NASDAQ · United States · Health Technology
$4.07+0.04 (+0.99%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients - NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a poster will be presented at the 41st An
- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study - - Patients with stable or increased weight at three months had significantly longer overall survival than patients who lost weight at three months - - Overall survival was comparable among patients with moderate and deeper tumor volume reductions, suggesting presence of tumor reduction may be more important than depth of response - - Finding
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
- Trial in progress poster will highlight the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer patients -NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a trial in progress abstract featuring the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib in combination with modified gemcitabine/nab-pa
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.